咳嗽变异性哮喘的发病机制及研究进展
|
摘要
随着对哮喘认识的逐渐加深,越来越多的研究关注其发病机制。咳嗽变异性哮喘(CVA)是以咳嗽为唯一或主要临床表现的特殊类型哮喘,其气道炎症机制复杂且尚未完全阐明。本篇综述将对目前CVA发病机制的研究及其进展做简要总结。
引文
[1]BOUSQUET J,DAHL R,KHALTAEV N.Global alliance againstchronic respiratory diseases[J].Allergy,2007,62(3):216-223.
[2]CORRAO W M,BRAMAN S S,IRWIN R S.Chronic cough asthe sole presenting manifestation of bronchial asthma[J].NEngl J Med,1979,300(12):633-637.
[3]MATSUMOTO H,NIIMI A,TABUENA R P,et al.Airwaywall thickening in patients with cough variant asthma and non-asthmatic chronic cough[J].Chest,2007,131(4):1042-1049.
[4]LIU M,LIU K,ZHU N,et al.Inflammatory mediators in in-duced sputum and airway hyperresponsiveness in cough variantasthma during long-term inhaled corticosteroid treatment[J].Mediat Inflamm,2012,2012:403868.
[5]陈树煜,方泽葵,方思,等.典型哮喘与咳嗽变异性哮喘的小气道功能差异分析[J].南方医科大学学报,2017,37(3):330-336.
[6]NIIMI A.Cough and asthma[J].Curr Respir Med Rev,2011,7(1):47-54.
[7]DICPINIGAITIS P V,DOBKIN J B,REICHEL J.Antitussive ef-fect of the leukotriene receptor antagonist zafirlukast in subjectswith cough-variant asthma[J].J Asthma,2002,39(4):291-297.
[8]DICPINIGAITIS P V.Chronic cough due to asthma:ACCP evi-dence-based clinical practice guidelines[J].Chest,2006,129(1 suppl):75S-79S.
[9]DE DIEGO A,MARTINEZ E,PERPINA M,et al.Airway in-flammation and cough sensitivity in cough-variant asthma[J].Allergy,2005,60(11):1407-1411.
[10]CAO C,PENG C,LAN F,et al.Proteomic analysis of sputumreveals novel biomarkers for various presentations of asthma[J].J Transl Med,2017,15(1):171.
[11]BERRY M,MORGAN A,SHAW D E,et al.Pathological fea-tures and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma[J].Thorax,2007,62(12):1043-1049.
[12]LAMBRECHT B N,HAMMAD H.The immunology of asthma[J].Nat Immunol,2015,16(1):45-56.
[13]OGAWA Y,DURU E A,AMEREDES B T.Role of IL-10 inthe resolution of airway inflammation[J].Curr Mol Med,2008,8(5):437-445.
[14]O′GARRA A,BARRAT F J,CASTRO A G,et al.Strategiesfor use of IL-10 or its antagonists in human disease[J].Immu-nol Rev,2008,223(1):114-131.
[15]周洋,张家洪.苏黄止咳胶囊联合沙美特罗/丙酸氟替卡松对咳嗽变异性哮喘患者气道炎症的影响[J].实用医学杂志,2016,32(2):298-299.
[16]HUMBERT M,MENZ G,YING S,et al.The immunopatholo-gy of extrinsic(atopic)and intrinsic(non-atopic)asthma:more similarities than differences[J].Immunol Today,1999,20(11):528-533.
[17]张莉,马礼兵,向旭东.CD4+T淋巴细胞在哮喘发病中的新认识[J].实用医学杂志,2011,27(4):704-706.
[18]ROBINSON D S.Regulatory T cells and asthma[J].Clin ExpAllergy,2009,39(9):1314-1323.
[19]TAMM M,RICHARDS D H,BEGHéB,et al.Inhaled cortico-steroid and long-actingβ2-agonist pharmacological profiles:ef-fective asthma therapy in practice[J].Resp Med,2012,106:S9-S19.
[20]ANDERSON G P.Endotyping asthma:new insights into keypathogenic mechanisms in a complex,heterogeneous disease[J].Lancet,2008,372(9643):1107-1119.
[21]ZHAO Y,YANG J,GAO Y,et al.Th17 immunity in patientswith allergic asthma[J].Int Arch Allergy Imm,2010,151(4):297-307.
[22]DINH-XUAN A T,ANNESI-MAESANO I,BERGER P,et al.Contribution of exhaled nitric oxide measurement in airway in-flammation assessment in asthma.A position paper from theFrench Speaking Respiratory Society[J].Rev Mal Respir,2015,32(2):193-215.
[23]SHIMODA T,OBASE Y,KISHIKAWA R,et al.The fraction-al exhaled nitric oxide and serum high sensitivity C-reactive pro-tein levels in cough variant asthma and typical bronchial asthma[J].Allergol Int,2013,62(2):251-257.
[24]KOREVAAR D A,WESTERHOF G A,WANG J,et al.Diag-nostic accuracy of minimally invasive markers for detection ofairway eosinophilia in asthma:a systematic review and meta-analysis[J].Lancet Respir Med,2015,3(4):290-300.
[25]CHEN F,HUANG X,LIN G,et al.Validity of fractional ex-haled nitric oxide and small airway function indices in diagnosisof cough-variant asthma[J].J Asthma,2017,55(7):750-755.
[26]方思,陈树煜,何熹,等.呼出气一氧化氮与脉冲振荡技术对亚急性咳嗽患者筛查咳嗽变异性哮喘的价值[J].中华医学杂志,2017(30):2338-2343.
[27]TANG W,ZHOU J,MIAO L,et al.Clinical features in pa-tients of cough variant asthma with normal and high level of ex-haled fractional nitric oxide[J].Clin Respir J,2018,12(2):595-600.
[28]KIM H B,ECKEL S P,KIM J H,et al.Exhaled NO:determi-nants and clinical application in children with allergic airwaydisease[J].Allergy Asthma Immunol Res,2016,8(1):12-21.
[29]YI F,CHEN R,LUO W,et al.Validity of fractional exhalednitric oxide in diagnosis of corticosteroid-responsive cough[J].Chest,2016,149(4):1042-1051.
[30]HSU J Y,WANG C Y,CHENG Y W,et al.Optimal value offractional exhaled nitric oxide in inhaled corticosteroid treatmentfor patients with chronic cough of unknown cause[J].J ChinMed Assoc,2013,76(1):15-19.
[31]MANUYAKORN W,HOWARTH P H,HOLGATE S T.Airwayremodelling in asthma and novel therapy[J].Asian Pac J Aller-gy,2013,31(1):3.
[32]AL-MUHSEN S,JOHNSON J R,HAMID Q.Remodelling in asthma[J].J Allergy Clin Immun,2011,128:451-462.
[33]MATSUMOTO H,NIIMI A,TAKEMURA M,et al.Features ofcough variant asthma and classic asthma during methacholine-in-duced brochoconstriction:a cross-sectional study[J].Cough,2009,5(1):3.
[34]DAMERA G,FOGLE H W,LIM P,et al.Vitamin D inhibitsgrowth of human airway smooth muscle cells through growth fac-tor-induced phosphorylation of retinoblastoma protein and check-point kinase 1[J].Brit J Pharmacol,2009,158(6):1429-1441.
[35]马礼兵.ANP信号调控CD4+T细胞及其在过敏性哮喘中的作用研究[D].中南大学,2012.
[36]GUNTUR V P,REINERO C R.The potential use of tyrosine ki-nase inhibitors in severe asthma[J].Curr Opin Allergy Cl,2012,12(1):68-75.
[37]GIOVANNA TEZZA,FEDEFICA MAZZEI.Attilio Bonen Epi-genetics of allergy[J].Early Hum Dev,2013,89(1):20-21.
[38]JANSEN P C,WINERDAL M E,MARITS P,et al.FOXP3promoter demethylation reveals the committed Treg populationin humans[J].PLo S One,2008,3(2):e1612.
[39]TOBEN C,BAUNE B T.An Act of balance between adaptiveand maladaptive immunity in depression:a role for T lympho-cytes[J].J Neuroimmune Pharm,2015,10(4):595-609.
[40]CHIBA Y,MISAWA M.Micro RNAs and their therapeutic po-tential for human disesses:Mi R-133a and bronchial smoothmuscle hyperresponsiveness in asthma[J].J Pharmacol Sci,2010,114(3):246-268.
[2]CORRAO W M,BRAMAN S S,IRWIN R S.Chronic cough asthe sole presenting manifestation of bronchial asthma[J].NEngl J Med,1979,300(12):633-637.
[3]MATSUMOTO H,NIIMI A,TABUENA R P,et al.Airwaywall thickening in patients with cough variant asthma and non-asthmatic chronic cough[J].Chest,2007,131(4):1042-1049.
[4]LIU M,LIU K,ZHU N,et al.Inflammatory mediators in in-duced sputum and airway hyperresponsiveness in cough variantasthma during long-term inhaled corticosteroid treatment[J].Mediat Inflamm,2012,2012:403868.
[5]陈树煜,方泽葵,方思,等.典型哮喘与咳嗽变异性哮喘的小气道功能差异分析[J].南方医科大学学报,2017,37(3):330-336.
[6]NIIMI A.Cough and asthma[J].Curr Respir Med Rev,2011,7(1):47-54.
[7]DICPINIGAITIS P V,DOBKIN J B,REICHEL J.Antitussive ef-fect of the leukotriene receptor antagonist zafirlukast in subjectswith cough-variant asthma[J].J Asthma,2002,39(4):291-297.
[8]DICPINIGAITIS P V.Chronic cough due to asthma:ACCP evi-dence-based clinical practice guidelines[J].Chest,2006,129(1 suppl):75S-79S.
[9]DE DIEGO A,MARTINEZ E,PERPINA M,et al.Airway in-flammation and cough sensitivity in cough-variant asthma[J].Allergy,2005,60(11):1407-1411.
[10]CAO C,PENG C,LAN F,et al.Proteomic analysis of sputumreveals novel biomarkers for various presentations of asthma[J].J Transl Med,2017,15(1):171.
[11]BERRY M,MORGAN A,SHAW D E,et al.Pathological fea-tures and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma[J].Thorax,2007,62(12):1043-1049.
[12]LAMBRECHT B N,HAMMAD H.The immunology of asthma[J].Nat Immunol,2015,16(1):45-56.
[13]OGAWA Y,DURU E A,AMEREDES B T.Role of IL-10 inthe resolution of airway inflammation[J].Curr Mol Med,2008,8(5):437-445.
[14]O′GARRA A,BARRAT F J,CASTRO A G,et al.Strategiesfor use of IL-10 or its antagonists in human disease[J].Immu-nol Rev,2008,223(1):114-131.
[15]周洋,张家洪.苏黄止咳胶囊联合沙美特罗/丙酸氟替卡松对咳嗽变异性哮喘患者气道炎症的影响[J].实用医学杂志,2016,32(2):298-299.
[16]HUMBERT M,MENZ G,YING S,et al.The immunopatholo-gy of extrinsic(atopic)and intrinsic(non-atopic)asthma:more similarities than differences[J].Immunol Today,1999,20(11):528-533.
[17]张莉,马礼兵,向旭东.CD4+T淋巴细胞在哮喘发病中的新认识[J].实用医学杂志,2011,27(4):704-706.
[18]ROBINSON D S.Regulatory T cells and asthma[J].Clin ExpAllergy,2009,39(9):1314-1323.
[19]TAMM M,RICHARDS D H,BEGHéB,et al.Inhaled cortico-steroid and long-actingβ2-agonist pharmacological profiles:ef-fective asthma therapy in practice[J].Resp Med,2012,106:S9-S19.
[20]ANDERSON G P.Endotyping asthma:new insights into keypathogenic mechanisms in a complex,heterogeneous disease[J].Lancet,2008,372(9643):1107-1119.
[21]ZHAO Y,YANG J,GAO Y,et al.Th17 immunity in patientswith allergic asthma[J].Int Arch Allergy Imm,2010,151(4):297-307.
[22]DINH-XUAN A T,ANNESI-MAESANO I,BERGER P,et al.Contribution of exhaled nitric oxide measurement in airway in-flammation assessment in asthma.A position paper from theFrench Speaking Respiratory Society[J].Rev Mal Respir,2015,32(2):193-215.
[23]SHIMODA T,OBASE Y,KISHIKAWA R,et al.The fraction-al exhaled nitric oxide and serum high sensitivity C-reactive pro-tein levels in cough variant asthma and typical bronchial asthma[J].Allergol Int,2013,62(2):251-257.
[24]KOREVAAR D A,WESTERHOF G A,WANG J,et al.Diag-nostic accuracy of minimally invasive markers for detection ofairway eosinophilia in asthma:a systematic review and meta-analysis[J].Lancet Respir Med,2015,3(4):290-300.
[25]CHEN F,HUANG X,LIN G,et al.Validity of fractional ex-haled nitric oxide and small airway function indices in diagnosisof cough-variant asthma[J].J Asthma,2017,55(7):750-755.
[26]方思,陈树煜,何熹,等.呼出气一氧化氮与脉冲振荡技术对亚急性咳嗽患者筛查咳嗽变异性哮喘的价值[J].中华医学杂志,2017(30):2338-2343.
[27]TANG W,ZHOU J,MIAO L,et al.Clinical features in pa-tients of cough variant asthma with normal and high level of ex-haled fractional nitric oxide[J].Clin Respir J,2018,12(2):595-600.
[28]KIM H B,ECKEL S P,KIM J H,et al.Exhaled NO:determi-nants and clinical application in children with allergic airwaydisease[J].Allergy Asthma Immunol Res,2016,8(1):12-21.
[29]YI F,CHEN R,LUO W,et al.Validity of fractional exhalednitric oxide in diagnosis of corticosteroid-responsive cough[J].Chest,2016,149(4):1042-1051.
[30]HSU J Y,WANG C Y,CHENG Y W,et al.Optimal value offractional exhaled nitric oxide in inhaled corticosteroid treatmentfor patients with chronic cough of unknown cause[J].J ChinMed Assoc,2013,76(1):15-19.
[31]MANUYAKORN W,HOWARTH P H,HOLGATE S T.Airwayremodelling in asthma and novel therapy[J].Asian Pac J Aller-gy,2013,31(1):3.
[32]AL-MUHSEN S,JOHNSON J R,HAMID Q.Remodelling in asthma[J].J Allergy Clin Immun,2011,128:451-462.
[33]MATSUMOTO H,NIIMI A,TAKEMURA M,et al.Features ofcough variant asthma and classic asthma during methacholine-in-duced brochoconstriction:a cross-sectional study[J].Cough,2009,5(1):3.
[34]DAMERA G,FOGLE H W,LIM P,et al.Vitamin D inhibitsgrowth of human airway smooth muscle cells through growth fac-tor-induced phosphorylation of retinoblastoma protein and check-point kinase 1[J].Brit J Pharmacol,2009,158(6):1429-1441.
[35]马礼兵.ANP信号调控CD4+T细胞及其在过敏性哮喘中的作用研究[D].中南大学,2012.
[36]GUNTUR V P,REINERO C R.The potential use of tyrosine ki-nase inhibitors in severe asthma[J].Curr Opin Allergy Cl,2012,12(1):68-75.
[37]GIOVANNA TEZZA,FEDEFICA MAZZEI.Attilio Bonen Epi-genetics of allergy[J].Early Hum Dev,2013,89(1):20-21.
[38]JANSEN P C,WINERDAL M E,MARITS P,et al.FOXP3promoter demethylation reveals the committed Treg populationin humans[J].PLo S One,2008,3(2):e1612.
[39]TOBEN C,BAUNE B T.An Act of balance between adaptiveand maladaptive immunity in depression:a role for T lympho-cytes[J].J Neuroimmune Pharm,2015,10(4):595-609.
[40]CHIBA Y,MISAWA M.Micro RNAs and their therapeutic po-tential for human disesses:Mi R-133a and bronchial smoothmuscle hyperresponsiveness in asthma[J].J Pharmacol Sci,2010,114(3):246-268.